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Abstract
Background Perioperative transfusion of allogeneic blood has been hypothesized to have an immunomodulatory effect and
influence survival in several cancer types. This study evaluates the association between receipt of leucocyte-depleted and
non-depleted allogeneic blood and survival following esophagectomy for cancer.
Methods A retrospective analysis was performed including 291 patients with esophageal cancers who underwent
transthoracic en bloc esophagectomy and extended mediastinal lymphadenectomy. Neoadjuvant chemoradiation was
administered in 152 (52.2%) patients. Perioperative blood transfusions were quantified and the potential prognostic cutoff
for transfused units was calculated according to LeBlanc.
Results The median number of perioperative blood transfusions was 2 (0–24), and 106 patients (36.4%) received no
transfusions. Patients with one or less blood transfusion showed a significantly improved survival compared to patients
receiving more than one unit (p<0.009). In multivariate analysis, blood transfusion categories showed significance
(p<0.015) next to pT, pN, pM category, and residual tumor categories (R-categories). Separate analysis of 183 patients
treated after the mandatory introduction of leukocyte-depleted blood transfusions detected a strong tendency, but no
significant difference in survival for patients getting one or less or more than one transfusion (p=0.056). Receipt of
leukocyte-depleted versus non-depleted units, however, had no influence on survival (p=0.766).
Conclusions The need for perioperative allogeneic blood transfusions is significantly associated with poorer survival
following resection for esophageal cancer by univariate and multivariate analysis. Our data suggest that the reduction of
leukocytes in allogeneic transfusions is not sufficient to overcome the negative influence on survival.
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Introduction
Since the 1970s, perioperative blood transfusion has been
thought to have an immunomodulatory effect. Though
beneficial in transplantation surgery, it was postulated to be
associated with decreased survival rates in various tumor
types including esophageal cancer.1
The cause of this phenomenon is still unclear. Some
authors assumed decreased survival with perioperative
blood transfusion to be rather a reflection of circumstances
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necessitating transfusion.2,3 Others demonstrated a signifi-
cantly independent relationship by multivariate analysis.4–6
Studies exploring underlying mechanisms showed a
decreasing number of circulating T lymphocytes with a
decreased ratio of helper-to-suppressor T lymphocytes.
Natural killer cell function was reduced like the interleukin-2
production, whereas the number of suppressor T lympho-
cytes and production of prostaglandin-E was increased. In
summary, allogeneic blood transfusion decreases T-cell-
based immune response, an important mechanism to remove
tumor cells from the body. Furthermore, macrophage
migration was found to be impaired preventing antigen
presentation.1
In animal models, allogeneic blood transfusion was
associated with increased tumor growth and frequency of
metastases.7 These effects could possibly be abolished
through depleting donor blood of leukocytes.8,9 In patients
undergoing colorectal surgery receiving leukocyte-depleted
transfusions, postoperative infections decreased significant-
ly despite impaired natural killer cell function.10
Previous studies dealing with blood transfusion in
esophageal surgery did not deal with leukocyte-depleted
transfusions.2–6,11 After the mandatory introduction in
Germany in 2001, pre-storage leukocyte-depleted products
are used without exception, with an amount of contaminat-
ing leukocytes of less than 1×106/unit according to the
European consensus.12
In this retrospective analysis, we evaluated the prognostic
influence of perioperative allogeneic blood transfusions in
patients with esophagectomy for esophageal cancer. Compar-
isons were made between patients treated with leukocyte-
depleted versus non-depleted units of blood.
Material and Methods
A retrospective study was performed with 305 patients who
underwent esophagectomy between January 1997 and
October 2006 in the Department of Visceral and Vascular
Surgery, University of Cologne, Germany. To exclude the
effects of surgery-related postoperative complications, 14
patients (4.8%) dying within 90 days after the operation
were excluded.
From 291 study patients, there were 234 men (80.4%)
and 57 women (19.6%) with a median age of 62 years
(range, 18.9 to 83.2 years).
Histopathological examination of the resected specimens
revealed squamous cell cancer in 137 patients (47.1%),
adenocarcinoma in 148 cases (50.9%), and other rare
entities in six patients (2.1%).
Because of locally advanced disease, 152 patients
(52.2%) received standardized neoadjuvant chemoradiation
with cisplatin, 5-fluorouracil, and 36 Gy as described in
detail.13 Four to five weeks after completion of chemo-
radiation, transthoracic en bloc esophagectomy with two-
field lymphadenectomy was performed. Relevant clinical
and histopathological data are summarized in Table 1.
To determine the number of perioperative blood trans-
fusions, an observation period of 30 days after operation
was chosen. One unit equals approximately 280-ml (250–
310 ml) suspension of packed red blood cells.
An Edict of the Paul-Ehrlich-Institute allowed only the
use of leukocyte-depleted blood transfusions after October
1, 2001 in Germany. Pre-storage depletion achieves an
amount of contaminating leukocytes of less than 1×106/
unit according to the European consensus.12
Statistical Analysis
The median follow-up was 4.9 years (range, 1.1–11 years).
All living patients had a follow-up of more than 12 months.
Table 1 Patient Characteristics
Parameter Number of patients (%)
Median age, 62.0 years (range, 18.9–83.2 years)
Gender n=291
Male 234 (80.4%)
Female 57 (19.6%)
Histology n=291
Squamous cell cancer 137 (47.1%9
Adenocarcinoma 148 (50.9%)
Others 6 (2.1%)
Neoadjuvant treatment n=291
No 139 (47.8%)
Yes 152 (52.2%)
T category n=291
pT0 27 (9.3%)
pT1 68 (23.4%)
pT2 58 (19.9%)
pT3 136 (46.7%)
pT4 2 (0.7%)
N category n=291
pN0 149 (51.2%)
pN1 142 (48.8%)
M category n=291
cpM0 249 (85.6%)
cpM1 42 (14.4%)
Grading n=291
G1 5 (1.7%)
G2 148 (50.9%)
G3 135 (46.4%)
G4 3 (1%)
R category n=291
R0 276 (94.8%)
R1/2 15 (5.2%)
pT local invasiveness, pN lymph node metastases, c/pM distant
metastases (categories according to UICC), y neoadjuvant therapy, n
number of patients
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We analyzed the best cutoff value for number of blood
transfusions (ec) as a prognostic variable by simulating the
log-rank test for groups defined by (ec < c) and (ec > c) for
observed values of the covariate for the entire data set. This
tree-based method for prognostic stratification was de-
scribed by LeBlanc.14
Kaplan–Meier plots were used to describe survival
distribution.15 The log-rank test was used to evaluate for
survival differences.16 For multiple comparisons, the
Holm–Sidak method was used. In addition, 95% confidence
intervals (95% CI) for the different survival curves were
calculated. Cox regression analysis was applied to identify
independent prognostic variables. The level of significance
was set to p<0.05.
All statistical tests were performed using the Software
Package SPSS forWindows, version 14.0, Chicago, IL, USA.
Results
Transfused Allogeneic Blood Units
Transfusion demand ranged from 0 to 24 U of blood.
Median was 2 U and mean value was 3.5±4.5 U. One
hundred six patients (36.4%) received no allogeneic blood
transfusions, five patients only one unit (1.7%).
There were 108 cases before October 1, 2001, whereas
after introduction of leukocyte-depleted blood, 183 patients
were analyzed. In the first period, 18 patients (16.7%) were
not transfused, and one person received a single unit
(0.9%). In the second period, 88 patients (48.1%) were
operated without allogeneic blood and four patients with a
single unit (2.2%). The median number of blood trans-
fusions decreased significantly from 4 to 1 U (p<0.001).
Survival Analysis
The 5-year survival rate for all patients was 35±3%. A
significant cutoff value was identified between 0–1
and >1 U of transfused blood (Fig. 1). Five-year survival
rates for patients with 0–1 U transfused blood was 46±7%
compared to 29±4% for patients with >1 U [median
survival 3.52 (0.99–6.04) vs. 2.1 years (1.66–2.54), p<
0.009] (Fig. 2).
Currently, 126 patients are alive, 158 died, and seven
patients were lost to follow-up.
In a subgroup analysis of 183 patients treated after the
mandatory introduction of leukocyte-depleted blood trans-
fusions in October 2001, no significant difference in
survival (p=0.056, Fig. 3) was found for patients getting
one or less or more than one transfusion [5-year survival
rates, 39±9% compared to 29±7%; median survival was
3.24 (1.51–4.98) vs. 2.25 (1.66–2.84) years].
The comparison of transfused patients before and after
October 2001 failed to show a significant difference (p=
0.766) between non-depleted units (5-year survival, 30±5%)
versus leukocyte-depleted units (5-year survival, 30±7%) on
survival (Fig. 4) [median survival was 1.96 (1.33–2.60) vs.
2.34 years (1.65–3.03)].
Multivariate Analysis
Cox regression analysis for all patients including pT, pN,
c/pM categories, resection categories, histology, neoadjuvant
therapy, and blood transfusion categories showed sig-
nificance for pT [p<0.002, HR 2.9 (1.5–5.6) (pT3–pT1)],
pN [p<0.0001, HR 2.0 (1.4–3.1)], pM [p<0.011, HR 1.7
(1.1–2.5)], residual tumor categories (R-categories) [p<0.005,
HR 2.4 (1.3–4.5)], and blood transfusion categories
[p<0.015, HR 1.6 (1.1–2.3)].
Discussion
In the present study, patients receiving none or 1 U of
allogeneic blood had a significantly better 5-year survival
rate than patients getting more than 1 U by univariate
analysis. In multivariate analysis, transfusion category
remained independently associated with survival like pT,
pN, c/pM, and resection categories.
In the literature, several studies dealing with blood trans-
fusion and survival in patients with esophageal carcinoma
are published, most of them with mixed histological types.
Langley et al.4 demonstrated transfusion of more than
3 U to be an independent negative predictor for survival by
Figure 1 Analysis of the best cutoff value for number of blood
transfusions (ec) as a prognostic variable by simulating the log-rank
test for groups defined by (ec < c) and (ec > c) for observed values of
the covariate for the entire data set.14
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multivariate analysis. This observation is supported by
Tachibana et al.5 who identified more than 2 U as
independent prognostic factor in squamous cell cancer
patients. As in our study, they excluded all patients dying
within 90 days after the operation to exclude effects of
surgery-related postoperative complications. Dresner et al.6
confirmed transfusion of more than 4 U as independent
factor in esophageal cancer patients.
In contrast, Swisher et al.2 demonstrated blood transfu-
sion of more than 8 U to be associated with decreased long-
term survival by univariate analysis. This, however, was
due to an increased number of postoperative complications
which then eliminated significance in multivariate analysis.
The authors suggest that complications that necessitate
transfusions were responsible for this observation because
no increase in local or distant tumor recurrences were
Figure 3 Kaplan–Meier curves
based on blood transfusions
(≤1 versus >1; cutoff according
to LeBlanc) for the subgroup of
183 patients treated after the
mandatory introduction of
leukocyte-depleted blood trans-
fusions in October 2001. Log-
rank failed level of significance
(p=0.056) for patients getting
more than one transfusion
(5-year survival, 29±7%) versus
≤1 (5-year survival 39±9%).
Figure 2 Kaplan–Meier curves
based on blood transfusions
(≤1 versus >1; cutoff according
to LeBlanc, log-rank, p<0.009).
Overall survival rate at 5 years
for all patients was 35±3%.
584 J Gastrointest Surg (2009) 13:581–586
identified. Nozoe et al.3 also found that the occurrence of
postoperative complications was a prognostic factor,
whereas perioperative allogeneic blood transfusions were
not in patients with squamous cell cancer.
Craig et al.11 identified that blood transfusion is only
associated with reduced short-term survival for patients in
advanced stage III. They hypothesized that occult micro-
metastases progressed in this subgroup due to transfusion-
induced immunomodulatory effects.
This is in line with a study by Motoyama et al.17
comparing autologous with allogeneic blood transfusions.
Differences were seen in prolonged disease-free survival for
patients getting autologous blood, but not for recurrence
rates or survival times following recurrence. Takemura et
al.18 demonstrated that patients with nodal involvement and
T3/4 tumors had a significantly improved survival after
autologous compared to allogeneic transfusion.
Because contaminating donor leukocytes could be
responsible for this effect, we sub-analyzed our data for
operations pre- and post-introduction of leukocyte-depleted
blood transfusions (less than 1×106 leukocytes/unit accord-
ing to the European consensus).12 The comparison of
transfused patients failed to show an association between
non-depleted versus leukocyte-depleted units on survival.
The different follow-up time periods for these groups
represent a potential bias, but analysis of Kaplan–Meier
curves showed a similarity within the first years of follow-
up. The shorter follow-up in the population of leukocyte-
depleted blood transfusion might also be the reason for the
strong tendency but missing significance of the amount of
transfused units towards reduced survival.
In colorectal surgery, Jensen et al.19 found after
transfusion with whole blood an increase in postoperative
infectious complications accompanied by elevated IL-2R
and IL-6 levels and decreased lymphocyte proliferation and
CD4/CD8 ratio in leukocyte-depleted blood only slight and
transient changes similar to non-transfused patients. In
comparison between buffy-coat-poor and leukocyte-depleted
blood transfusion, differences in wound infections and
abscesses could be also noticed; however, the mortality rate
was not different,20 even after 7 years of follow-up in
contrast to non-transfused patients.21
Also, in colorectal cancer, Houbiers et al.22 found no
difference in disease-free survival, cancer recurrence rate,
or overall infections between patients receiving buffy-coat-
poor or leukocyte-depleted blood. In contrast to non-
transfused patients, both groups had a reduced survival
and higher infection rate. The effect of blood transfusion on
survival might therefore not be mediated by allogeneic
leukocytes alone, but also cellular and humoral components
could be able to alter the immune potential.23
In summary, the need for perioperative allogeneic blood
transfusions is associated with poorer survival following
resection by transthoracic en bloc esophagectomy for esoph-
ageal carcinomas by univariate and multivariate analysis. Our
data suggest that either the reduction of leukocytes is not
sufficient or that besides leukocytes other cellular or humoral
elements may also influence survival after blood transfusion.
Figure 4 Kaplan–Meier curves
for patients receiving non-
depleted (5-year survival, 30±
5%) versus leukocyte-depleted
transfusions (5-year survival,
30±7%), log-rank, p=0.766.
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